Our study provides a novel and effective therapeutic option for cardiac hypertrophy and heart failure, consisting of AAV-mediated delivery of a RNA-based dON neutralizing transcriptional activity of the NFATc1-c4 family of transcription factors. Here, NFATC1 is linked to cardiac hypertrophy.